Condition
Primary Amyloidosis
Total Trials
5
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
20%
1 of 5 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (2)
Trial Status
Completed5
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02555969Completed
Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis
NCT00651937Phase 2Completed
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
NCT01707264Phase 1CompletedPrimary
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
NCT00883623Phase 2CompletedPrimary
A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
NCT00807872Phase 1CompletedPrimary
Radioimmunoimaging of AL Amyloidosis
Showing all 5 trials